Stability indicating ultraviolet spectroscopic method for the estimation of ezetimibe and carvedilol

Pharmazie

Volumn 61, Issue 9, 2006, Pages 766-769

  Imran, M ^a   Singh, R S P ^a   Chandran, S ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; EZETIMIBE; SOLVENT; WATER;

ARTICLE; DEGRADATION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; SPECTROSCOPY; TABLET; ULTRAVIOLET RADIATION;

ADRENERGIC BETA-ANTAGONISTS; ANTILIPEMIC AGENTS; AZETIDINES; CALIBRATION; CARBAZOLES; DRUG STABILITY; PROPANOLAMINES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLVENTS; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, NEAR-INFRARED;

EID: 33749025270     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. rd edition, Marcel Dekker, New York, 1997, pp 153, 216-269.
2. Catapano AL (2001) Ezetimibe: a selective inhibitor of cholesterol absorption. Eur Heart J Suppl 3(suppl-E): E6-E10.
3. Clader JW (2004) The discovery of ezetimibe: a view from outside the receptor. J Med Chem 47: 1-9.
4. do Carmo Borges NC, Mendes GD, de Oliveira Silva D, Marcondes Rezende V, Barrientos-Astigarrage RE, De Nucci G (2005) Quantification of carvedilol in human plasma by highperformance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci 822: 253-262.
5. Dulin B, Abraham WT (2004) Pharmacology of carvedilol. Am J Cardiol 93: 3-6.
6. Hokama N, Hobara N, Kameya H, Ohshiro S, Sakanashi M (1999) Rapid and simple micro-determination of carvedilol in rat plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 732: 233-238.
7. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use: Harmonized Tripartite Guideline on Validation of Analytical Procedures: Methodology, Recommended for Adoption at step 4 of the ICH process on November 1996 by the ICH Steering Committee, Published by IFPMA, Switzerland.
8. Reiff K (1987) High-performance liquid chromatograpic method for the determination of carvedilol and its desmethyl metabolite in body fluids. J Chromatogr B Biomed Sci Appl 413: 355-362.
9. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layoff T, Vishwanathan CT, Cork CE, McDowall RD, Pitman KA, Spector S (1992) Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies. Pharm Res 9: 588-592.
10. th Edition, Rockville, MD, 2000, pp 2149-2157.
11. van Heek M, Davis H (2002) Pharmacology of ezetimibe. Eur Heart J Suppl 3(suppl-J): J5-J8.
12. van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, Davis HR Jr (1997) In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 283: 157-163.
13. Xu LX, Hui N, Ma LY, Wang HY (2005) Study on fluorescence property of carvedilol and determination of carvedilol by fluorimetry. Mol Biomol Spectroscopy 61: 855-859.
14. Yang E, Wang S, Kratz J, Cyronak MJ (2004) Stereoselective analysis of carvedilol in human plasma using HPLC/MS/MS after chiral derivatization. J Pharm Biomed Anal 36: 609-615.